Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study.

Bi, L.; Zhang, Z.; Zhou, B.; Zuo, X.; Zhang, H.; Zhang, M.; Zheng, Y.; Li, Y.; He, L.; Jiang, Z.; Wang, Y.; Li, X.; Wei, W.; Gu, J.; Wang, G.; Liu, Y.; Wu, Z.; Liu, H.; He, D.; Lv, Z.; Li, Z.; Xu, Huji; Dong, L.; Wu, H.; Chen, H.; Bao, C.; Song, H.; Jiang, L.; Liu, X.; Boehnlein, M.; Dunkel, J.; Shao, J.; Harris, K.

Links

ORCID

Tools

Export citation

Search in Google Scholar

Efficacy and safety of certolizumab pegol in combination with methotrexate in methotrexate-inadequate responder Chinese patients with active rheumatoid arthritis: 24-week results from a randomised, double-blind, placebo-controlled phase 3 study.

Journal article published in 2018 by L. Bi, Z. Zhang, B. Zhou, X. Zuo, H. Zhang, M. Zhang, Y. Zheng, Y. Li, L. He, Z. Jiang, Y. Wang, X. Li, W. Wei, J. Gu, G. Wang and other authors.

This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Preprint: policy unknown

Upload

Postprint: policy unknown

Upload

Published version: policy unknown

Upload